98%
921
2 minutes
20
Purpose: It can be challenging to localize the lesions in certain cases of primary hyperparathyroidism. Recently, it has been proposed that assessing the localization of parathyroid lesions with dynamic images enhances the diagnostic power of standard MRI (magnetic resonance imaging) due to the hypervascular structure of these lesions. In this study, we aimed to evaluate the success of four-dimensional dynamic perfusion MRI (4D MRI) in localizing parathyroid lesions.
Methods: Thirty patients who underwent 4-dimensional dynamic MRI diagnosed with primary hyperparathyroidism and indications for surgery, whose USG (ultrasonography) and/or Tc 99m sestamibi SPECT scan were negative or discordant, were included. The sensitivity and positive predictive values (PPV) were calculated for each imaging modality.
Results: Of the 30 patients, 29 had parathyroid adenoma, and one had parathyroid hyperplasia in histopathologic examination. 4D MRI accurately identified the location of parathyroid lesions in 25 of 30 patients (sensitivity 83.3%, PPV 96.1%), whereas USG successfully identified the lesion location in 21 patients (sensitivity 70%, PPV 91.3%) and Tc 99m sestamibi SPECT scan in 17 patients (sensitivity 56.7%, PPV 94.4%). The sensitivity of the combination of three imaging modalities was found to be 96.7%.
Conclusion: 4D MRI can be utilized as a complementary imaging modality to localize parathyroid lesions, offering the advantage of no ionizing radiation, especially when USG and/or Tc 99m sestamibi SPECT scans cannot reliably identify them.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12227485 | PMC |
http://dx.doi.org/10.1007/s12020-025-04239-2 | DOI Listing |
J Clin Endocrinol Metab
September 2025
Endocrinology & Nutrition Department, Hospital Universitario de Vall d´Hebron, Barcelona, Spain.
Objective: Pituitary adenomas (PAs) are one of the three major lesions in Multiple Endocrine Neoplasia type 1 (MEN1), with a prevalence of 32 to 58%, yet their specific risk factors remain unidentified. This study aimed to identify predictors influencing PA occurrence in MEN1.
Methods: This nationwide, multicenter, retrospective cohort study involved 240 MEN1 patients, 55.
Horm Metab Res
September 2025
Clinical Biochemistry, The Royal Wolverhampton NHS Trust, Black Country Pathology Services, Wolverhampton, United Kingdom of Great Britain and Northern Ireland.
Parathyroid hormone (PTH) assays are not standardized and therefore PTH results are interpreted using manufacturer-provided assay-specific reference intervals. Assay-specific PTH reference intervals, however, do not account for between-assay differences and lead to discordance in the diagnosis of normocalcaemic primary hyperparathyroidism (NCPHPT). PTH increases with age independent of vitamin D, renal function, phosphate and ionized calcium.
View Article and Find Full Text PDFCureus
August 2025
Department of ENT, University Hospital Center Hassan II, Fez, MAR.
Parathyroid carcinoma is an exceptionally rare malignant tumor of the parathyroid gland. Clinically, it most often presents as severe primary hyperparathyroidism. Diagnosis relies on histopathological analysis, although it is often difficult to establish due to the lack of clearly pathognomonic criteria.
View Article and Find Full Text PDFAnn Surg Oncol
September 2025
Department of Surgery, Hospital of the University of Pennsylvania, Philadelphia, USA.
Calcif Tissue Int
September 2025
Department of Endocrinology, Post-Graduate Institute of Medical Education and Research (PGIMER), 001, Nehru Extension Block, Chandigarh, India.
Rare diseases, defined by the 2002 Rare Disease Act, affect fewer than 5 in 10,000 individuals. Rare metabolic bone diseases (MBDs), such as osteogenesis imperfecta, hypophosphatasia, osteopetrosis, and other unclassified disorders, can disrupt bone development and remodeling, posing diagnostic and management challenges. This study analyzed data from the rarembd.
View Article and Find Full Text PDF